摘要
目的观察中药血脂清对高血压合并代谢综合征患者血脂及颈动脉内膜中层厚度的影响。方法将90例患者随机分为3组,即阿托伐他汀组、血脂清组及联合治疗组,每组各30例。阿托伐他汀组予阿托伐他汀10mg,每晚1次;血脂清组予血脂清1包,3次/d;联合治疗组予阿托伐他汀10mg,每晚1次+血脂清1包,3次/d;疗程均为8周。测定3组治疗前后血脂、肝功能及IMT的变化,并计算IMT与颈总动脉管腔内径的比率。结果与治疗前比较,治疗后3组TC、LDL-C、IMT均降低,血脂清组及联合治疗组TG降低,HDL-C升高,差异均有统计学意义(P<0.05)。治疗后3组之间两两比较,TG、LDL-C降低差异无统计学意义(P>0.05);TC降低,阿托伐他汀组、联合治疗组均优于血脂清组,差异有统计学意义(P<0.01),而阿托伐他汀组与联合治疗组之间比较,差异无统计学意义(P>0.05);HDL-C升高,3组之间两两比较差异均有统计学意义(P<0.05),且联合治疗组优于血脂清组;IMT降低,联合治疗组均优于阿托伐他汀组、血脂清组,差异有统计学意义(P<0.01),而阿托伐他汀组与血脂清组比较,差异无统计学意义(P>0.05)。治疗期间,阿托伐他汀组肝功能轻度升高3例,血脂清组及联合治疗组未见不良反应。结论血脂清可以有效调脂,与西药阿托伐他汀联合使用疗效更佳,并可以显著降低IMT,是治疗高血压合并代谢综合征患者的一种有效方案。
Objective To observe the influence of xuezhiqing on blood lipid and carotid intima-media thickness of patients with hypertension with metabolic syndrome. Methods 90 patients were randomly divided into 3 groups, of which each group got 30 patients for this study project including atorvastatin group （atorvastatin 10 mg qn）, XZQ group （XZQ 1 bag tid） and combined treatment group （atorvastatin 10 mg qn＋XZQ 1 bag tid）. The treatment course of 3 groups was 8 weeks. The blood lipid, hepatic function and carotid intima-media thickness were determined before and after treatment in 3 groups. Results After treatment, TC, LDL-C and IMT were significantly decreased in 3 groups, TG decreased and HDL-C increased in XZQ group and combined treatment group, as compared with those before treatment （P 0.05）.The difference of TG and LDL-C did not reach a significant value between the 3 groups at post-treatment （P 0.05）.The atorvastatin group and combined treatment group were both superior to XZQ group in decreasing effect of TC（P 0.01）,but no significant differences were detected between atorvastatin group and combined treatment group（P 0.05）. The increasing effect of HDL-C had statistical significances in the pair wise comparison among the three groups （P 0.05）, in which the combined treatment group better than the XZQ group. And the combined treatment group was better than the other two groups, which had no statistical significance, in the decreasing effect of IMT. There were only 3 cases of elevated liver function in atorvastatin group among all the patients during the treatment period. Conclusion XZQ can correct the abnormal blood lipid and the effect will be better, that can also decrease significantly IMT on combined with atorvostatin, which is an effective therapy on patients with hypertension with metabolic syndrome.
出处
《中国医药科学》
2012年第21期21-23,共3页
China Medicine And Pharmacy
基金
福建省泉州市科技局重点项目(2009Z40)
关键词
高血压
代谢综合征
血脂清
颈动脉内膜中层厚度
Hypertension
Metabolic syndrome
Xuezhiqing
Carotid intima-media thickness
